FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Arbuckle Stuart A (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					3. 08	Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] 3. Date of Earliest Transaction (Month/Day/Year) 08/15/2022 4. If Amendment, Date of Original Filed (Month/Day/Year)							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, COO 6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) BOSTON MA 02210												X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	State) (Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Yea		if any	emed on Date, (Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Benefic Owned		ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	ction(s)		(Instr. 4)
Common Stock				08/15/2022				М		6,571	Α	\$155.	.57	67	,451	D	
Common Stock				08/15/2022				S ⁽¹⁾		1,254	D	\$300.3	3(2)(3)	66	5,197	D	
Common Stock				08/15/2022				S ⁽¹⁾		4,242	4,242 D \$301.		1(2)(4)	61,955		D	
Common Stock				08/15/2022				S ⁽¹⁾		400	D	\$302.5	302.55(2)(5)		61,555		
Common Stock				08/15/2022				S ⁽¹⁾		2,339	D	D \$303.78		59,216		D	
Common Stock				08/15/2022				S ⁽¹⁾		6,990	D	\$304.67(2)(7)		52,226		D	
Common Stock 08/1				08/15/20	08/15/2022					6,948	D	\$305.38(2)(8)		45,278		D	
Common Stock													1	140	I	401(k)	
		T	able							isposed o s, convert				wned			
1. Title of Derivative Security (Instr. 3)	f 2. 3. Transaction 3A. Deeme Execution or Exercise (Month/Day/Year) if any		eemed ition Date,	ed 4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title Amour Securi Underl Deriva	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Price of erivative ecurity istr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	Ownersh Form: Direct (D or Indirect (I) (Instr.	Beneficial Ownership t (Instr. 4)	

Explanation of Responses:

\$155.57

1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

08/15/2022

2. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

6.571

(Instr. 3, 4 and 5)

(A) (D)

Code

M

Date

Exercisable

(9)

- 3. Open market sales reported on this line occurred at a weighted average price of \$300.30 (range \$300.00 to \$300.73).
- 4. Open market sales reported on this line occurred at a weighted average price of \$301.61 (range \$301.09 to \$302.01).
- 5. Open market sales reported on this line occurred at a weighted average price of \$302.55 (range \$302.13 to \$302.90).
- 6. Open market sales reported on this line occurred at a weighted average price of \$303.78 (range \$303.13 to \$304.09).
- 7. Open market sales reported on this line occurred at a weighted average price of \$304.67 (range \$304.13 to \$305.12).
- 8. Open market sales reported on this line occurred at a weighted average price of \$305.38 (range \$305.13 to \$305.83).
- 9. Fully vested.

Stock Option

Buv)

(Right to

Remarks:

/s/ Joy Liu, Attorney-in-Fact

08/17/2022

** Signature of Reporting Person

Amount or Number

6,571

\$0.00

Expiration Date

02/05/2028

Title

Commor

Stock

Date

(Instr. 4)

0

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.